|
Warm Autoimmune Hemolytic Anemia (wAIHA)
Warm autoimmune hemolytic anemia (wAIHA) is the most common type (60-70%) of autoimmune hemolytic anemia (AIHA). In most cases, wAIHA is due an immunoglobulin G (IgG) autoantibody that binds to red blood cells (RBC), leading to hemolysis.
Current recommendations for managing people with wAIHA are largely based on case series and retrospective studies involving off-label medications. Also, while there are currently no medications specifically approved to treat wAIHA, data are emerging on new... |
|
|
Myasthenia Gravis Research Highlights: AAN 2023
This 30-minute CME program highlights the latest clinical research about myasthenia gravis, a rare, autoimmune disease that targets the neuromuscular junction.
Treatment of myasthenia gravis is highly individualized and depends greatly on the myasthenia gravis subtype of each patient as well as each patient’s comorbidities. There are currently four drugs approved by the FDA, eculizumab, efgartigimod, ravulizumab, and rozanolixizumab. There are also treatments in development. Clinical tria... |
|
Putting the Freeze on Cold Agglutinin Disease
STATEMENT OF NEED
Cold agglutinin disease (CAD) is a rare subtype of autoimmune hemolytic anemia (AIHA) in which antibodies cause hemolysis at cold temperatures, generally between 37º to 39º Fahrenheit. Approximately 1 in a million people are affected by CAD annually, with onset usually occurring between the ages of 40 and 80 years. Individuals commonly experience fatigue, dizziness, palpitations, and shortness of breath caused by the anemia; jaundice caused by degradation of hemoglobin i... |
|
|
Myasthenia Gravis and the Complement System
This 45-minute CME-accredited program, hosted by James F Howard Jr, MD, Professor of Neurology, Medicine & Allied Health at The University of North Carolina at Chapel Hill, highlights the connection between the complement system and myasthenia gravis in regards to the pathophysiology and treatment of this rare disease.
After participating in the activity, learners should be better able to:
- Review the pathophysiology of MG.
- Describe the role of the complement system in MG.
- Descr... |
|
|
Gastroenterology 2024 - LIVE STREAMING
The Comprehensive 2024 Gastroenterology Update
This highly rated Harvard Medical School CME program ensures participants are current with state-of-the-art GI strategies and clinical practices. It covers recent advances and their impact on clinical approaches and on patient outcomes. Updates, best practices, and new guidelines are presented by nationally recognized GI experts and master clinicians.
Practical, Results-Driven Education
Highlights of the 2024 program include:
• Updated... |
|
|
Internal Medicine Comprehensive Review and Update 2024 - LIVE STREAMING
Comprehensive, Evidence-Based Updates for Internal Medicine and Its Subspecialties
This program, the 64th annual Internal Medicine Update from the leading clinical faculty of Harvard Medical School and Massachusetts General Hospital, provides comprehensive, high-yield instruction to ensure clinicians are current with the latest evidence and best practices to optimize patient care.
This program covers the breadth of Internal Medicine subspecialties, including:
• Cardiovascular Medicine
â€... |
|
|
Neuromyelitis Optica Spectrum Disorder: Updates on Diagnosis and Treatment Management
Neuromyelitis optica spectrum disorder (NMOSD) is a rare, relapsing, autoimmune disease of the central nervous system that is characterized by inflammation in the optic nerve and spinal cord. Unfortunately, early stages of NMOSD are frequently misdiagnosed as multiple sclerosis or other diseases. Diagnosis is typically based on the presence of key clinical characteristics"aquaporin-4 (AQP4) antibody status and magnetic resonance imaging. The application of newer diagnostic criteria may as... |
|
|
The latest insights into rare blood disorders: Diagnosis and treatment strategies
Because immune-mediated rare blood disorders are uncommon, healthcare providers often lack the knowledge and experience necessary to identify, diagnose, and treat them in accordance with best practices. As a result, there are significant gaps in care, including delays in diagnosis and suboptimal treatment. To ensure that more patients with these rare disorders are offered quality, evidence-based care, it is essential that healthcare providers possess up-to-date information about best practices... |
|